Main Line Health Center-Exton — Exton, Pennsylvania

Main Line Health Center-Exton is a clinical research site located in Exton, Pennsylvania, United States 19341.

Crixeo Clinical Trials Trust Score: 25/100 (FAILING). This profile has not yet been claimed by the site owner.

Main Line Health Center-Exton has participated in 36 clinical trials with 31 currently active.

Therapeutic areas: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8.

Sponsors: Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, SWOG Cancer Research Network.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Exton

Browse all research sites in Pennsylvania · View every site in Exton

Sponsor Feasibility Report

Trust Score: 25/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Main Line Health Center-Exton?

Main Line Health Center-Exton has a Crixeo Trust Score of 25/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Main Line Health Center-Exton conducted?

Main Line Health Center-Exton has 36 clinical trials on record, with 31 currently active. Their work covers Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8.

Is Main Line Health Center-Exton accredited by Crixeo Clinical Trials?

Main Line Health Center-Exton has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Main Line Health Center-Exton?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.